AL622

prodrug that releases both PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo(3,4-d)pyrimidine), a c-Src kinase inhibitor, and AL621; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Coudray, Laëtitia: 1 article (12/2012)
2.	Halaoui, Ruba: 1 article (12/2012)
3.	Huang, Ying: 1 article (12/2012)
4.	Jean-Claude, Bertrand J: 1 article (12/2012)
5.	Larroque-Lombard, Anne-Laure: 1 article (12/2012)
6.	Lauwagie, Sylvia: 1 article (12/2012)
7.	Ning, Na: 1 article (12/2012)
8.	Rao, Suman: 1 article (12/2012)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 12/01/2012 - "After confirming its binary c-Src-EGFR targeting potency of AL622, we analyzed its potency in isogenic NIH3T3 cells transfected with EGFR and HER2 and human breast cancer cells known to be dominated by c-Src function. "